Department of Virology, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Medical Research Centre, Institut of Medical Research and Medicinal Plants Studies, Yaoundé, Cameroon.
PLoS Negl Trop Dis. 2020 Aug 26;14(8):e0008589. doi: 10.1371/journal.pntd.0008589. eCollection 2020 Aug.
Accurate data on the Lassa virus (LASV) human case fatality rate (CFR) and the prevalence of LASV in humans, rodents and other mammals are needed for better planning of actions that will ultimately reduce the burden of LASV infection in sub-Saharan Africa. In this systematic review with meta-analysis, we searched PubMed, Scopus, Africa Journal Online, and African Index Medicus from 1969 to 2020 to obtain studies that reported enough data to calculate LASV infection CFR or prevalence. Study selection, data extraction, and risk of bias assessment were conducted independently. We extracted all measures of current, recent, and past infections with LASV. Prevalence and CFR estimates were pooled using a random-effect meta-analysis. Factors associated with CFR, prevalence, and sources of between-study heterogeneity were determined using subgroup and metaregression analyses. This review was registered with PROSPERO, CRD42020166465. We initially identified 1,399 records and finally retained 109 reports that contributed to 291 prevalence records from 25 countries. The overall CFR was 29.7% (22.3-37.5) in humans. Pooled prevalence of LASV infection was 8.7% (95% confidence interval: 6.8-10.8) in humans, 3.2% (1.9-4.6) in rodents, and 0.7% (0.0-2.3) in other mammals. Subgroup and metaregression analyses revealed a substantial statistical heterogeneity explained by higher prevalence in tissue organs, in case-control, in hospital outbreak, and surveys, in retrospective studies, in urban and hospital setting, in hospitalized patients, and in West African countries. This study suggests that LASV infections is an important cause of death in humans and that LASV are common in humans, rodents and other mammals in sub-Saharan Africa. These estimates highlight disparities between sub-regions, and population risk profiles. Western Africa, and specific key populations were identified as having higher LASV CFR and prevalence, hence, deserving more attention for cost-effective preventive interventions.
准确的拉沙病毒(LASV)人类病死率(CFR)和 LASV 在人类、啮齿动物和其他哺乳动物中的流行数据对于更好地规划行动至关重要,这些行动最终将减轻 LASV 感染在撒哈拉以南非洲的负担。在这项系统评价和荟萃分析中,我们检索了 PubMed、Scopus、Africa Journal Online 和 African Index Medicus 从 1969 年到 2020 年,以获取报告了足够数据来计算 LASV 感染 CFR 或流行率的研究。研究选择、数据提取和偏倚风险评估都是独立进行的。我们提取了所有当前、最近和过去 LASV 感染的指标。使用随机效应荟萃分析汇总了流行率和 CFR 估计值。使用亚组和荟萃回归分析确定了与 CFR、流行率和研究间异质性来源相关的因素。这项综述已在 PROSPERO 上注册,注册号为 CRD42020166465。我们最初确定了 1399 条记录,最终保留了 109 份报告,这些报告来自 25 个国家的 291 份流行率记录。人类的总体 CFR 为 29.7%(22.3-37.5)。人类 LASV 感染的合并流行率为 8.7%(95%置信区间:6.8-10.8),啮齿动物为 3.2%(1.9-4.6),其他哺乳动物为 0.7%(0.0-2.3)。亚组和荟萃回归分析表明,组织器官、病例对照、医院暴发和调查、回顾性研究、城市和医院环境、住院患者以及西非国家中更高的流行率解释了很大的统计学异质性。这项研究表明,LASV 感染是人类死亡的一个重要原因,LASV 在撒哈拉以南非洲的人类、啮齿动物和其他哺乳动物中很常见。这些估计值突出了次区域之间以及人群风险特征之间的差异。西非和特定的关键人群被确定为 LASV CFR 和流行率较高,因此需要更加关注具有成本效益的预防干预措施。